Trade CRISPR Therapeutics AG - CRSP CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.18 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 0.1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 37.98 |
| Open | 37.87 |
| 1-Year Change | -45.95% |
| Day's Range | 36.99 - 37.88 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 27, 2025 | 37.98 | -0.86 | -2.21% | 38.84 | 39.16 | 37.77 |
| Mar 26, 2025 | 39.12 | -1.38 | -3.41% | 40.50 | 40.78 | 39.00 |
| Mar 25, 2025 | 40.83 | -1.57 | -3.70% | 42.40 | 42.40 | 40.71 |
| Mar 24, 2025 | 42.54 | 0.79 | 1.89% | 41.75 | 42.65 | 41.75 |
| Mar 21, 2025 | 41.16 | 0.71 | 1.76% | 40.45 | 41.60 | 40.20 |
| Mar 20, 2025 | 41.10 | -0.05 | -0.12% | 41.15 | 42.37 | 40.95 |
| Mar 19, 2025 | 41.85 | 1.31 | 3.23% | 40.54 | 42.71 | 40.46 |
| Mar 18, 2025 | 40.85 | -1.15 | -2.74% | 42.00 | 42.00 | 40.35 |
| Mar 17, 2025 | 42.74 | 0.89 | 2.13% | 41.85 | 43.23 | 41.25 |
| Mar 14, 2025 | 42.05 | -0.39 | -0.92% | 42.44 | 43.40 | 41.86 |
| Mar 13, 2025 | 41.89 | -1.21 | -2.81% | 43.10 | 44.08 | 41.52 |
| Mar 12, 2025 | 43.25 | 0.73 | 1.72% | 42.52 | 43.86 | 42.30 |
| Mar 11, 2025 | 42.32 | -0.23 | -0.54% | 42.55 | 43.24 | 40.76 |
| Mar 10, 2025 | 43.29 | -1.44 | -3.22% | 44.73 | 45.85 | 42.62 |
| Mar 7, 2025 | 45.34 | 2.79 | 6.56% | 42.55 | 45.68 | 41.26 |
| Mar 6, 2025 | 43.09 | 0.50 | 1.17% | 42.59 | 43.59 | 41.45 |
| Mar 5, 2025 | 43.80 | 0.65 | 1.51% | 43.15 | 44.15 | 42.28 |
| Mar 4, 2025 | 44.03 | 3.58 | 8.85% | 40.45 | 44.19 | 40.45 |
| Mar 3, 2025 | 42.02 | -2.63 | -5.89% | 44.65 | 45.07 | 41.94 |
| Feb 28, 2025 | 43.69 | 1.13 | 2.66% | 42.56 | 44.45 | 41.94 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
CRISPR Therapeutics AG Company profile
CRISPR Therapeutics AG, a gene editing company, focuses on developing transformative gene-based medicines for serious diseases. The company develops its products using Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), a revolutionary gene editing technology that allows for precise directed changes to genomic DNA. It has a portfolio of therapeutic programs in a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company''s lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta thalassemia or severe sickle cell disease in which a patient''s hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. The company is also developing CTX110, a donor-derived gene-edited allogeneic CAR-T therapy targeting cluster of differentiation 19 positive malignancies. In addition, it is developing allogeneic CAR-T programs comprising CTX120 targeting B-cell maturation antigen for the treatment of multiple myeloma; and CTX130 for the treatment of solid tumors and hematologic malignancies. Further, the company engages in developing regenerative medicine programs in diabetes; and in vivo and other genetic disease programs to treat glycogen storage disease Ia, duchenne muscular dystrophy, cystic fibrosis, and hurler syndrome. It partners with biopharma companies, academic centers, universities, and other organizations. The company has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to develop and commercialize products for the treatment of Duchenne M. CRISPR Therapeutics AG is headquartered in Zug, Switzerland.| Industry: | Biotechnology & Medical Research (NEC) |
Baarerstrasse 14
ZUG
ZUG 6300
CH
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com